Risks Associated With Lentiviral Vector Exposures and Prevention Strategies

Overview

Journal J Occup Environ Med

Specialty Environmental Health

Date 2016 Dec 9

PMID 27930472

Citations 73

Authors

Ryan Schlimgen

John Howard

Dawn Wooley

Maureen Thompson

Lindsey R Baden

Otto O Yang

David C Christiani

Gustavo Mostoslavsky

David V Diamond

Elizabeth Gilman Duane

Karen Byers

Thomas Winters

Jeffrey A Gelfand

Gary Fujimoto

T Warner Hudson

Jatin M Vyas

Affiliations

Soon will be listed here.

Abstract

Lentiviral vectors (LVVs) are powerful genetic tools that are being used with greater frequency in biomedical laboratories and clinical trials. Adverse events reported from initial clinical studies provide a basis for risk assessment of occupational exposures, yet many questions remain about the potential harm that LVVs may cause. We review those risks and provide a framework for principal investigators, Institutional Biosafety Committees, and occupational health professionals to assess and communicate the risks of exposure to staff. We also provide recommendations to federal research and regulatory agencies for tracking LVV exposures to evaluate long-term outcomes. U.S. Food and Drug Administration approved antiviral drugs for HIV have theoretical benefits in LVV exposures, although evidence to support their use is currently limited. If treatment is appropriate, we recommend a 7-day treatment with an integrase inhibitor with or without a reverse transcriptase inhibitor within 72 hours of exposure.

Citing Articles

The design of retroviral vectors used in the CAR-T products, risk management, and future perspective.

Yin H, Wei X MedComm (2020). 2025; 6(2):e70067.

PMID: 39866836 PMC: 11758153. DOI: 10.1002/mco2.70067.

RNA Structure: Past, Future, and Gene Therapy Applications.

Haseltine W, Hazel K, Patarca R Int J Mol Sci. 2025; 26(1.

PMID: 39795966 PMC: 11719923. DOI: 10.3390/ijms26010110.

Cultivated meat microbiological safety considerations and practices.

Powell D, Li D, Smith B, Chen W Compr Rev Food Sci Food Saf. 2024; 24(1):e70077.

PMID: 39731713 PMC: 11681928. DOI: 10.1111/1541-4337.70077.

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Chekaoui A, Garofalo M, Gad B, Staniszewska M, Chiaro J, Pancer K Clin Exp Med. 2024; 25(1):24.

PMID: 39720956 PMC: 11669620. DOI: 10.1007/s10238-024-01541-7.

Clinical and Translational Landscape of Viral Gene Therapies.

Yudaeva A, Kostyusheva A, Kachanov A, Brezgin S, Ponomareva N, Parodi A Cells. 2024; 13(22).

PMID: 39594663 PMC: 11592828. DOI: 10.3390/cells13221916.

References

de Ravin S, Wu X, Moir S, Anaya-OBrien S, Kwatemaa N, Littel P . Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016; 8(335):335ra57. PMC: 5557273. DOI: 10.1126/scitranslmed.aad8856. View

Cockrell A, Ma H, Fu K, McCown T, Kafri T . A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther. 2006; 14(2):276-84. DOI: 10.1016/j.ymthe.2005.12.015. View

Ramezani A, Hawley R . Overview of the HIV-1 Lentiviral Vector System. Curr Protoc Mol Biol. 2008; Chapter 16:Unit 16.21. DOI: 10.1002/0471142727.mb1621s60. View

Rothe M, Modlich U, Schambach A . Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther. 2013; 13(6):453-68. DOI: 10.2174/15665232113136660006. View

Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D . Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016; 8(7):702-11. PMC: 4931286. DOI: 10.15252/emmm.201505869. View

Kafri T . Gene delivery by lentivirus vectors an overview. Methods Mol Biol. 2004; 246:367-90. DOI: 10.1385/1-59259-650-9:367. View

Eberle J, Habermann J, Gurtler L . HIV-1 infection transmitted by serum droplets into the eye: a case report. AIDS. 2000; 14(2):206-7. DOI: 10.1097/00002030-200001280-00019. View

Zufferey R, Dull T, Mandel R, Bukovsky A, Quiroz D, Naldini L . Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12):9873-80. PMC: 110499. DOI: 10.1128/JVI.72.12.9873-9880.1998. View

Stein S, Ott M, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A . Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010; 16(2):198-204. DOI: 10.1038/nm.2088. View

10.

Cronin J, Zhang X, Reiser J . Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005; 5(4):387-98. PMC: 1368960. DOI: 10.2174/1566523054546224. View

11.

Jones R, Brosseau L . Aerosol transmission of infectious disease. J Occup Environ Med. 2015; 57(5):501-8. DOI: 10.1097/JOM.0000000000000448. View

12.

Kuhar D, Henderson D, Struble K, Heneine W, Thomas V, Cheever L . Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013; 34(9):875-92. DOI: 10.1086/672271. View

13.

Howe S, Mansour M, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H . Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008; 118(9):3143-50. PMC: 2496964. DOI: 10.1172/JCI35798. View

14.

Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F . In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259):263-7. DOI: 10.1126/science.272.5259.263. View

15.

Schulte P, Mundt D, Nasterlack M, Mulloy K, Mundt K . Exposure registries: overview and utility for nanomaterial workers. J Occup Environ Med. 2011; 53(6 Suppl):S42-7. DOI: 10.1097/JOM.0b013e31821aebed. View

16.

Siegel J, Rhinehart E, Jackson M, Chiarello L . 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control. 2007; 35(10 Suppl 2):S65-164. PMC: 7119119. DOI: 10.1016/j.ajic.2007.10.007. View

17.

Rossetti M, Cavarelli M, Gregori S, Scarlatti G . HIV-derived vectors for gene therapy targeting dendritic cells. Adv Exp Med Biol. 2012; 762:239-61. DOI: 10.1007/978-1-4614-4433-6_9. View

18.

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F . Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010; 467(7313):318-22. PMC: 3355472. DOI: 10.1038/nature09328. View

19.

Pedrosa P, Cardoso T . Viral infections in workers in hospital and research laboratory settings: a comparative review of infection modes and respective biosafety aspects. Int J Infect Dis. 2011; 15(6):e366-76. PMC: 7110847. DOI: 10.1016/j.ijid.2011.03.005. View

20.

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View